Author: News Room
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Caribou Biosciences, Inc. (NASDAQ: CRBU) securities between July 14, 2023 and July 16, 2024. Caribou is a clinical-stage biopharmaceutical company that purports to develop genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the U.S. and internationally. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Caribou Biosciences, Inc. (CRBU) Misled…
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a class action was filed on behalf of purchasers of DMC Global Inc. (NASDAQ: BOOM) securities between May 3, 2024 and November 4, 2024. DMC Global is a diversified industrial company. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that DMC Global Inc. (BOOM) Misled Investors Regarding its Operations and Financial Results According to the complaint, during the class period, defendants failed to disclose that: (i) the goodwill associated with…
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a class action was filed on behalf of all shareholders who purchased stock pursuant and/or traceable to the BioAge Labs, Inc. (NASDAQ: BIOA) registration statement for the initial public offering (IPO) held on September 26, 2024. BioAge claims it is a “clinical stage biopharmaceutical company” that develops therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating…
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) — The “Home Equity Lending Market Report 2024” has been added to ResearchAndMarkets.com’s offering.The home equity lending market size is expected to see steady growth in the next few years. It will grow to $34.73 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The projected growth during the forecast period can be attributed to several factors, including the shift towards remote work, increasing real estate prices, a rise in home renovation activities, growth in residential properties, and higher disposable income. Key trends expected in this period include technological advancements and…
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) — The “Tonic-Clonic Seizures Treatment Market Report and Forecast 2024-2032” report has been added to ResearchAndMarkets.com’s offering.The tonic-clonic seizures treatment market was valued at USD 34.93 billion in 2023. The market is expected to grow at a CAGR of 6% during the period 2024-2032, reaching USD 55.84 billion by 2032. This growth is driven by the increased incidences of epilepsy across major regions, advancements in pharmaceutical research, rising awareness and diagnosis, and supportive government initiatives and investments in healthcare infrastructure. The United States leads the market due to advanced healthcare infrastructure, high awareness, and…
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) — The “Quantum Computing in Drug Discovery Market Report and Forecast 2024-2032” report has been added to ResearchAndMarkets.com’s offering.The global quantum computing in drug discovery market was valued at USD 400 million in 2023. The market is expected to grow at a CAGR of 13% during the period 2024-2032, reaching USD 1.20 billion by 2032 This growth is driven by the increasing adoption of artificial intelligence in the healthcare domain, advancements in quantum computing technology, rising investment from pharmaceutical companies, and supportive government policies and investments in healthcare research infrastructure. Quantum computing in drug…
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024. AstraZeneca describes itself as “a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.” For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP…
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) — The “Healthcare Facilities Management Market Report and Forecast 2024-2032” report has been added to ResearchAndMarkets.com’s offering. The healthcare facilities management market is anticipated to undergo substantial growth with a compounded annual growth rate (CAGR) of 10.3% during the forecast period of 2024 to 2032. Recently valued at USD 251.92 billion in 2023, the market is set to reach an estimated USD 608.22 billion by the year 2032, thanks in part to technological advancements within the global healthcare sector.Key Market InsightsThe increasing demand for healthcare services, the aging global population, and the surge in…
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) — The “CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region” report has been added to ResearchAndMarkets.com’s offering.The global CRISPR-based gene editing market size was estimated to be USD 4.14 billion in 2023 and is expected to reach USD 18.84 billion by 2034 with a CAGR of 14.76% during the forecast period 2024-2034. Continuous advancements in CRISPR technology, rising demand for gene therapy, more funding and investment, rising prevalence of genetic disorders, and a growing emphasis on personalized medicine will all fuel market expansion. The expanding range of…
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) — The “Alzheimer’s Drugs Market Report and Forecast 2024-2032” report has been added to ResearchAndMarkets.com’s offering.The Alzheimer’s drugs market was valued at USD 7.7 billion in 2023, driven by the increasing aging population and rising awareness about Alzheimer’s disease and related dementia across the 8 major markets. The market is expected to grow at a CAGR of 5.3% during the forecast period of 2024-2032, with the values likely to reach USD 12.3 billion by 2032. The Alzheimer’s drugs market is undergoing dynamic changes as advancements in science and technology reshape the landscape of treatment…